ACADIA Pharmaceuticals Files 8-K on Financials
Ticker: ACAD · Form: 8-K · Filed: 2024-11-06T00:00:00.000Z
Sentiment: neutral
Topics: financial-condition, results-of-operations
Related Tickers: ACAD
TL;DR
ACADIA dropped an 8-K on financials, standard stuff for investors.
AI Summary
On November 6, 2024, ACADIA Pharmaceuticals Inc. filed an 8-K report. The filing primarily concerns the company's financial condition and results of operations, indicating a standard disclosure of ongoing business activities. No specific financial figures or significant events were detailed in the provided excerpt.
Why It Matters
This filing provides an update on ACADIA Pharmaceuticals' financial condition and operational results, which is important for investors to assess the company's performance and stability.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report on financial condition and results of operations, with no indication of unusual risks or events.
Key Players & Entities
- ACADIA Pharmaceuticals Inc. (company) — Registrant
- November 06, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 000-50768 (filing_id) — SEC File Number
- 06-1376651 (tax_id) — IRS Employer Identification No.
- 12830 El Camino Real, Suite 400 (address) — Principal Executive Offices
- San Diego (city) — Principal Executive Offices
- California (state) — Principal Executive Offices
- 92130 (zip_code) — Principal Executive Offices
- (858) 558-2871 (phone_number) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing by ACADIA Pharmaceuticals Inc.?
The primary purpose of this 8-K filing is to report on the company's Results of Operations and Financial Condition, as well as Financial Statements and Exhibits.
On what date was this 8-K report filed?
This 8-K report was filed on November 06, 2024.
What is ACADIA Pharmaceuticals Inc.'s state of incorporation?
ACADIA Pharmaceuticals Inc. is incorporated in Delaware.
What is the principal executive office address for ACADIA Pharmaceuticals Inc.?
The principal executive office address is 12830 El Camino Real, Suite 400, San Diego, California 92130.
What is the SEC file number for ACADIA Pharmaceuticals Inc.?
The SEC file number for ACADIA Pharmaceuticals Inc. is 000-50768.
Filing Stats: 532 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-11-06 16:14:26
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ACAD The Nasdaq Stock Mar
Filing Documents
- acad-20241106.htm (8-K) — 40KB
- acad-ex99_1.htm (EX-99.1) — 212KB
- 0000950170-24-122322.txt ( ) — 378KB
- acad-20241106.xsd (EX-101.SCH) — 24KB
- acad-20241106_htm.xml (XML) — 5KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On November 6, 2024, Acadia Pharmaceuticals Inc. issued a press release announcing its financial results for the third quarter and nine months ended September 30, 2024. A copy of this press release is furnished herewith as Exhibit 99.1. Pursuant to the rules and regulations of the Securities and Exchange Commission, such exhibit and the information set forth therein and in this Item 2.02 have been furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to liability under that section nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing regardless of any general incorporation language.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release dated November 6, 2024. 104 Cover page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Acadia Pharmaceuticals Inc. Date: November 6, 2024 By: /s/ Jennifer J. Rhodes Jennifer J. Rhodes Executive Vice President, Chief Legal Officer & Secretary